Trial Profile
A 26-week, randomized, placebo- and active-comparator-controlled, parallel-group, double-blind, 2-part study to assess the safety and efficacy of etoricoxib 30 mg versus celecoxib 200 mg in patients with osteoarthritis (Study 2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Etoricoxib (Primary) ; Celecoxib
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 31 Oct 2005 New trial record.